
Bio-Path Holdings BPTH
Quarterly report 2025-Q3
added 01-13-2026
Bio-Path Holdings EV/EBITDA Ratio 2011-2026 | BPTH
Annual EV/EBITDA Ratio Bio-Path Holdings
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.24 | -0.17 | 0.407 | -0.0267 | -2.01 | -9.29 | -22.1 | -43 | -99 | -8.19 | -5.81 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 0.407 | -99 | -17.2 |
EV/EBITDA Ratio of other stocks in the Biotechnology industry
| Issuer | EV/EBITDA Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
-0.591 | - | 2.43 % | $ 254 M | ||
|
ARCA biopharma
ABIO
|
1.84 | - | 1052.0 % | $ 415 M | ||
|
Aeterna Zentaris
AEZS
|
4.4 | - | 5.93 % | $ 314 M | ||
|
Albireo Pharma
ALBO
|
-3.38 | - | -0.23 % | $ 916 M | ||
|
Aileron Therapeutics
ALRN
|
-0.0369 | - | 10.36 % | $ 9.8 M | ||
|
I-Mab
IMAB
|
595 | - | - | $ 866 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
10.7 | - | - | $ 40.3 B | ||
|
Genfit SA
GNFT
|
4.22 K | - | 2.54 % | $ 160 B | ||
|
Biophytis SA
BPTS
|
-17.6 | - | -13.47 % | $ 169 M | ||
|
Ascendis Pharma A/S
ASND
|
-15.7 | $ 221.35 | 2.7 % | $ 5 B | ||
|
Aptinyx
APTX
|
-1.56 | - | -39.0 % | $ 4.57 M | ||
|
NextCure
NXTC
|
-2.03 | $ 10.07 | 1.31 % | $ 28.6 M | ||
|
Midatech Pharma plc
MTP
|
0.796 | - | -18.52 % | $ 27.3 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
-3.42 | - | -1.52 % | $ 24.7 M | ||
|
Amphastar Pharmaceuticals
AMPH
|
17.3 | $ 19.62 | 2.03 % | $ 917 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
0.546 | - | - | $ 26.5 M | ||
|
Oragenics
OGEN
|
1.73 | $ 0.65 | 0.69 % | $ 1.4 M | ||
|
Ayala Pharmaceuticals
AYLA
|
0.785 | - | - | $ 7.46 M | ||
|
AgeX Therapeutics
AGE
|
-1.85 | - | -10.17 % | $ 12.2 K | ||
|
Acorda Therapeutics
ACOR
|
0.777 | - | -24.86 % | $ 820 K | ||
|
Atreca
BCEL
|
-2.76 | - | -11.76 % | $ 5.79 M | ||
|
Omeros Corporation
OMER
|
-1.59 | $ 10.49 | 3.05 % | $ 610 M | ||
|
Acasti Pharma
ACST
|
1.8 | - | 4.01 % | $ 150 M | ||
|
BeiGene, Ltd.
BGNE
|
-208 | - | 0.49 % | $ 251 B | ||
|
bluebird bio
BLUE
|
-0.805 | - | - | $ 546 M | ||
|
Институт стволовых клеток человека
ISKJ
|
14 | - | - | - | ||
|
Cara Therapeutics
CARA
|
-6.7 | - | -3.03 % | $ 260 M | ||
|
Adverum Biotechnologies
ADVM
|
-1.32 | - | - | $ 86.2 M | ||
|
Acer Therapeutics
ACER
|
-3.39 | - | 2.71 % | $ 14 M | ||
|
Advaxis
ADXS
|
-82.4 | - | -9.65 % | $ 45.9 M | ||
|
Avenue Therapeutics
ATXI
|
0.871 | - | -52.27 % | $ 4.45 M | ||
|
Autolus Therapeutics plc
AUTL
|
-1.38 | $ 1.36 | 3.03 % | $ 347 M | ||
|
Corbus Pharmaceuticals Holdings
CRBP
|
-0.248 | $ 8.29 | 1.34 % | $ 110 M | ||
|
CRISPR Therapeutics AG
CRSP
|
13.1 | $ 47.67 | 2.67 % | $ 4.29 B | ||
|
Cyclacel Pharmaceuticals
CYCC
|
0.195 | - | -5.98 % | $ 34.1 M | ||
|
ChemoCentryx
CCXI
|
-0.721 | - | - | $ 3.74 B | ||
|
Processa Pharmaceuticals
PCSA
|
-2.51 | $ 2.32 | -0.23 % | $ 3.04 M | ||
|
Dynavax Technologies Corporation
DVAX
|
12.8 | - | - | $ 2.02 B | ||
|
BioDelivery Sciences International
BDSI
|
8 | - | -4.8 % | $ 255 M | ||
|
Enochian Biosciences
ENOB
|
-7.22 | - | - | $ 40.5 M | ||
|
Aeglea BioTherapeutics
AGLE
|
-4.27 | - | - | $ 1.01 B | ||
|
CureVac N.V.
CVAC
|
-7.74 | - | - | $ 867 M | ||
|
Phathom Pharmaceuticals
PHAT
|
-4.73 | $ 10.39 | 3.28 % | $ 758 M | ||
|
Bellerophon Therapeutics
BLPH
|
0.0235 | - | -74.18 % | $ 955 K | ||
|
Akero Therapeutics
AKRO
|
-4.64 | - | - | $ 3.67 B | ||
|
BiomX
PHGE
|
0.969 | $ 4.81 | -3.41 % | $ 7.85 M | ||
|
Phio Pharmaceuticals Corp.
PHIO
|
1.55 | $ 1.26 | 3.28 % | $ 7.54 M | ||
|
Arbutus Biopharma Corporation
ABUS
|
-3.41 | $ 4.58 | 6.26 % | $ 878 M | ||
|
Homology Medicines
FIXX
|
-1.14 | - | 0.77 % | $ 53.4 M | ||
|
Akouos
AKUS
|
-1.13 | - | 0.23 % | $ 488 M |